Limits...
ABT ‐ 719 for the Prevention of Acute Kidney Injury in Patients Undergoing High ‐ Risk Cardiac Surgery: A Randomized Phase 2b Clinical Trial

View Article: PubMed Central - PubMed

ABSTRACT

Background: Patients undergoing cardiac surgeries with cardiopulmonary bypass (on‐pump) have a high risk for acute kidney injury (AKI). We tested ABT‐719, a novel α‐melanocyte‐stimulating hormone analog, for prevention of AKI in postoperative cardiac surgery patients.

Methods and results: This phase 2b randomized, double‐blind, placebo‐controlled trial included adult patients with stable renal function undergoing high‐risk on‐pump cardiac surgery in the United States and Denmark. Participants received placebo (n=61) or cumulative ABT‐719 doses of 800 (n=59), 1600 (n=61), or 2100 μg/kg (n=59). Primary outcome was development of AKI based on Acute Kidney Injury Network (AKIN) criteria, measured utilizing preoperative creatinine value and maximum value within 48 hours and urine output within the first 42 hours postsurgery. Secondary outcomes included incidence of AKI based on maximal changes from baseline in novel AKI biomarkers over a 72‐hour period after clamp release and length of intensive care unit stays through 90 days postsurgery. A total of 65.5%, 62.7%, and 69.6% of patients in the 800‐, 1600‐, and 2100‐μg/kg groups, respectively, developed AKI (stages 1, 2, and 3 combined) versus 65.5% in the placebo group (for each pair‐wise comparison with placebo, P=0.966, 0.815, and 0.605, respectively). Adverse events occurred at a similar rate in all treatment groups.

Conclusions: ABT‐719 treatment did not lower AKI incidence using AKIN criteria, influence the elevations of novel biomarkers, or change 90‐day outcomes in patients after cardiac surgery.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01777165.

No MeSH data available.


Effect of ABT‐719 treatment on the length of hospitalization. Length of stay in the hospital and intensive care unit (ICU) by 90 days postsurgery. Using the Kruskal–Wallis test for the comparisons between placebo and ABT‐719, P values were ≥0.06 for hospitalization and ≥0.09 for ICU stay.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5015281&req=5

jah31688-fig-0004: Effect of ABT‐719 treatment on the length of hospitalization. Length of stay in the hospital and intensive care unit (ICU) by 90 days postsurgery. Using the Kruskal–Wallis test for the comparisons between placebo and ABT‐719, P values were ≥0.06 for hospitalization and ≥0.09 for ICU stay.

Mentions: The respective median (range) lengths of hospital stay within 90 days after surgery for the ABT‐719 800‐, 1600‐, and 2100‐μg/kg and placebo groups were 8.0 (5.0–90.0), 8.0 (5.0–90.0), 10.0 (5.0–90.0), and 9.0 (5.0–90.0) days. Using ANOVA, P values were P=0.124, P=0.025, and P=0.773 versus placebo, respectively; P values were ≥0.06 using the Kruskal–Wallis test (Figure 4). The respective median (range) lengths of ICU stays for the ABT‐719 800‐, 1600‐, and 2100‐μg/kg and placebo groups were 3.0 (1.0–32.0), 2.0 (2.0–17.0), 4.0 (1.0–39.0), and 3.0 (2.0–47.0) days. Using ANOVA, P values were P=0.258, P=0.073, and P=0.906 versus placebo, respectively; P values were ≥0.09 using the Kruskal–Wallis test (Figure 4).


ABT ‐ 719 for the Prevention of Acute Kidney Injury in Patients Undergoing High ‐ Risk Cardiac Surgery: A Randomized Phase 2b Clinical Trial
Effect of ABT‐719 treatment on the length of hospitalization. Length of stay in the hospital and intensive care unit (ICU) by 90 days postsurgery. Using the Kruskal–Wallis test for the comparisons between placebo and ABT‐719, P values were ≥0.06 for hospitalization and ≥0.09 for ICU stay.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5015281&req=5

jah31688-fig-0004: Effect of ABT‐719 treatment on the length of hospitalization. Length of stay in the hospital and intensive care unit (ICU) by 90 days postsurgery. Using the Kruskal–Wallis test for the comparisons between placebo and ABT‐719, P values were ≥0.06 for hospitalization and ≥0.09 for ICU stay.
Mentions: The respective median (range) lengths of hospital stay within 90 days after surgery for the ABT‐719 800‐, 1600‐, and 2100‐μg/kg and placebo groups were 8.0 (5.0–90.0), 8.0 (5.0–90.0), 10.0 (5.0–90.0), and 9.0 (5.0–90.0) days. Using ANOVA, P values were P=0.124, P=0.025, and P=0.773 versus placebo, respectively; P values were ≥0.06 using the Kruskal–Wallis test (Figure 4). The respective median (range) lengths of ICU stays for the ABT‐719 800‐, 1600‐, and 2100‐μg/kg and placebo groups were 3.0 (1.0–32.0), 2.0 (2.0–17.0), 4.0 (1.0–39.0), and 3.0 (2.0–47.0) days. Using ANOVA, P values were P=0.258, P=0.073, and P=0.906 versus placebo, respectively; P values were ≥0.09 using the Kruskal–Wallis test (Figure 4).

View Article: PubMed Central - PubMed

ABSTRACT

Background: Patients undergoing cardiac surgeries with cardiopulmonary bypass (on‐pump) have a high risk for acute kidney injury (AKI). We tested ABT‐719, a novel α‐melanocyte‐stimulating hormone analog, for prevention of AKI in postoperative cardiac surgery patients.

Methods and results: This phase 2b randomized, double‐blind, placebo‐controlled trial included adult patients with stable renal function undergoing high‐risk on‐pump cardiac surgery in the United States and Denmark. Participants received placebo (n=61) or cumulative ABT‐719 doses of 800 (n=59), 1600 (n=61), or 2100 μg/kg (n=59). Primary outcome was development of AKI based on Acute Kidney Injury Network (AKIN) criteria, measured utilizing preoperative creatinine value and maximum value within 48 hours and urine output within the first 42 hours postsurgery. Secondary outcomes included incidence of AKI based on maximal changes from baseline in novel AKI biomarkers over a 72‐hour period after clamp release and length of intensive care unit stays through 90 days postsurgery. A total of 65.5%, 62.7%, and 69.6% of patients in the 800‐, 1600‐, and 2100‐μg/kg groups, respectively, developed AKI (stages 1, 2, and 3 combined) versus 65.5% in the placebo group (for each pair‐wise comparison with placebo, P=0.966, 0.815, and 0.605, respectively). Adverse events occurred at a similar rate in all treatment groups.

Conclusions: ABT‐719 treatment did not lower AKI incidence using AKIN criteria, influence the elevations of novel biomarkers, or change 90‐day outcomes in patients after cardiac surgery.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01777165.

No MeSH data available.